Dapagliflozin for patients with heart failure and reduced ejection fraction

被引：3
|
作者：
Ferry, Abigail [1 ]
机构：
[1] Allegheny Gen Hosp, Div Adv Heart Failure & Cardiac Transplant, Pittsburgh, PA 15212 USA
来源：
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2022年 / 35卷 / 09期
关键词：
dapagliflozin; heart failure; SGLT2; reduced ejection fraction; type; 2; diabetes; cardiovascular;
D O I：
10.1097/01.JAA.0000840504.15807.70
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The CDC estimates that national costs related to heart failure exceed $30 billion annually. Clinicians and researchers continue to aggressively pursue measures aimed at reducing morbidity and mortality among the 6.5 million adults affected by the disease. Dapagliflozin recently emerged as a promising FDA-approved therapy for patients with systolic heart failure, more commonly referred to as heart failure with reduced ejection fraction.
引用
收藏
页码：51 / 53
页数：3
相关论文
共 50 条
  • [1] Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
    Williams, David M.
    Evans, Marc
    DIABETES THERAPY, 2020, 11 (10) : 2207 - 2219
  • [2] Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
    Docherty, Kieran F.
    Ogunniyi, Modele O.
    Anand, Inder S.
    Desai, Akshay S.
    Diez, Mirta
    Howlett, Jonathan G.
    Nicolau, Jose C.
    O'Meara, Eileen
    Verma, Subodh
    Inzucchi, Silvio E.
    Kober, Lars
    Kosiborod, Mikhail N.
    Lindholm, Daniel
    Martinez, Felipe A.
    Bengtsson, Olof
    Ponikowski, Piotr
    Sabatine, Marc S.
    Sjostrand, Mikaela
    Solomon, Scott D.
    Langkilde, Anna Maria
    Jhund, Pardeep S.
    McMurray, John J., V
    JACC-HEART FAILURE, 2022, 10 (01) : 52 - 64
  • [3] Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
    Adamson, Carly
    Jhund, Pardeep S.
    Docherty, Kieran F.
    Belohlavek, Jan
    Chiang, Chern-En
    Diez, Mirta
    Drozdz, Jaroslaw
    Dukat, Andrej
    Howlett, Jonathan
    Ljungman, Charlotta E. A.
    Petrie, Mark C.
    Schou, Morten
    Inzucchi, Silvio E.
    Kober, Lars
    Kosiborod, Mikhail N.
    Martinez, Felipe A.
    Ponikowski, Piotr
    Sabatine, Marc S.
    Solomon, Scott D.
    Bengtsson, Olof
    Langkilde, Anna Maria
    Lindholm, Daniel
    Sjostrand, Mikaela
    McMurray, John J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (10) : 1662 - 1672
  • [4] Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice
    Montero-Perez-Barquero, Manuel
    Escobar-Cervantes, Carlos
    Arevalo-Lorido, Jose Carlos
    Conde-Martel, Alicia
    Salamanca-Bautista, Prado
    Manzano-Espinosa, Luis
    Formiga, Francesc
    Diez-Manglano, Jesus
    Cepeda, Jose Maria
    Gonzalez-Franco, Alvaro
    Casado-Cerrada, Jesus
    FUTURE CARDIOLOGY, 2023, 19 (06) : 343 - 351
  • [5] Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
    Butt, Jawad H.
    Docherty, Kieran F.
    Kosiborod, Mikhail N.
    Inzucchi, Silvio E.
    Kober, Lars
    Langkilde, Anna Maria
    Martinez, Felipe A.
    Bengtsson, Olof
    Ponikowski, Piotr
    Sabatine, Marc S.
    Sjoestrand, Mikaela
    Solomon, Scott
    Jhund, Pardeep S.
    Mcmurray, John J. V.
    JACC-HEART FAILURE, 2023, 11 (10) : 1411 - 1423
  • [6] Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
    Selvaraj, Senthil
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Miao, Zi Michael
    Fang, James C.
    Vardeny, Orly
    Desai, Akshay S.
    Shah, Sanjiv J.
    Lam, Carolyn S. P.
    Martinez, Felipe A.
    Inzucchi, Silvio E.
    de Boer, Rudolf A.
    Petersson, Magnus
    Langkilde, Anna Maria
    McMurray, John J., V
    Solomon, Scott D.
    JACC-HEART FAILURE, 2023, 11 (01) : 76 - 89
  • [7] Impact of Dapagliflozin on the Renal Function and Damage in Patients with Heart Failure with a Reduced Ejection Fraction
    Nakase, Masaaki
    Ninomiya, Kai
    Horiuchi, Yu
    Sekiguchi, Masahiro
    Watanabe, Yusuke
    Setoguchi, Naoto
    Asami, Masahiko
    Yahagi, Kazuyuki
    Yuzawa, Hitomi
    Komiyama, Kota
    Tanaka, Jun
    Aoki, Jiro
    Tanabe, Kengo
    INTERNAL MEDICINE, 2024, 63 (02) : 169 - 177
  • [8] SGLT2 inhibitors in heart failure with reduced ejection fraction
    Das, Uday Sankar
    Paul, Aritra
    Banerjee, Suvro
    EGYPTIAN HEART JOURNAL, 2021, 73 (01)
  • [9] Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
    Cunningham, Jonathan W.
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Kulac, Ian J.
    Desai, Akshay S.
    Jhund, Pardeep S.
    de Boer, Rudolf A.
    DeMets, David
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe
    Shah, Sanjiv J.
    McGrath, Martina M.
    O'Meara, Eileen
    Wilderang, Ulrica
    Lindholm, Daniel
    Petersson, Magnus
    Langkilde, Anna Maria
    McMurray, John J., V
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (14) : 1302 - 1310
  • [10] Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
    Reis, Joao
    Teixeira, Ana Rita
    Goncalves, Antonio Valentim
    Moreira, Rita Ilhao
    Silva, Tiago Pereira
    Timoteo, Ana Teresa
    Ferreira, Rui Cruz
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (10)
12345